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Background: For locally advanced or metastatic urothelial carcinoma, cisplatin-based chemotherapy is the standard
regimen. Nevertheless, almost all responding patients experience recurrence within the first year. When patients
who have received prior cisplatin-based therapy become resistant, combination therapy with gemcitabine and
paclitaxel has been reported. Few published case reports have addressed the utility of paclitaxel/cisplatin/gemcitabine
combination therapy as second-line chemotherapy for advanced or metastatic urothelial carcinoma. This is the first
report describing paclitaxel/cisplatin/gemcitabine combination therapy for metastatic urothelial carcinoma arising in a
transplanted renal allograft and leading to a successful outcome.
Case presentation: We present a case of metastatic urothelial carcinoma of a renal allograft in a 32-year-old
Japanese man with a history of kidney transplantation ten years prior. Because the patient’s serum creatinine
increased, hemodialysis was resumed, and the surgical allograft was removed. Multiple lung metastases were
resistant to gemcitabine/cisplatin adjuvant chemotherapy, so paclitaxel/cisplatin/gemcitabine combination
chemotherapy was instituted. After paclitaxel/cisplatin/gemcitabine chemotherapy, all pulmonary metastatic tumors
disappeared. The patient has survived without disease progression for more than four years since treatment.
Conclusion: Paclitaxel/cisplatin/gemcitabine combination therapy may be effective and lead to a survival advantage in
patients with locally advanced or metastatic urothelial carcinoma when used as second-line chemotherapy following
cisplatin-based therapy. However, further investigations may be required to confirm and evaluate the significance of
this treatment.
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For locally advanced or metastatic urothelial carci-
noma (UC), methotrexate/vinblastine/doxorubicin/cisplatin
(MVAC) [1] or gemcitabine/cisplatin (GC) [2] combi-
nation chemotherapy represents the standard regimen.
However when patients who have received prior cisplatin-
based therapy become resistant, there is no standard regi-
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unless otherwise stated.In general, malignant tumors occur more frequently in
renal transplant recipients receiving immunosuppressive
therapy. These malignancies are often more aggressive
and are associated with a poor prognosis [3-5].
We report a case of metastatic UC of a renal allograft
in a patient who showed long-term recurrence-free sur-
vival after being treated with a combination of paclitaxel,
cisplatin, and gemcitabine (PCG).Case presentation
A 32-year-old Japanese man presented with gross
hematuria. He had undergone a kidney transplant ten
years earlier for end-stage kidney disease with focalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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living kidney allograft from his 51-year-old father. On
presentation, an abdominal computed tomography (CT)
scan revealed a mass of approximately 4 cm in the allo-
graft collecting system. Chest CT showed multiple lung
metastases. The results of annual screening with abdom-
inal CT and ultrasonography had previously been nor-
mal. The patient’s Eastern Cooperative Oncology Group
(ECOG) performance status was 1 at this time.
Ureteroscopic biopsy was performed, and histopatho-
logy showed a grade 3, urothelial carcinoma. The clinical
diagnosis was renal pelvis cancer of stage T2N0M1 ac-
cording to the TNM classification of Malignant Tumors
(7th edition).
After hemodialysis was resumed, we planned GC neo-
adjuvant chemotherapy. Gemcitabine (GEM) was ad-
ministered at 1,000 mg/m2 on non-dialysis days 1, 8, and
15. Cisplatin (CDDP) was given intravenously at 35 mg/
m2 on dialysis day 2. This regimen was repeated every
four weeks.
However, the tumor showed progression following two
courses of GC treatment (Figure 1), so we decided to
perform renal allograftectomy. Histopathological exami-
nation confirmed a grade 3 invasive UC with final sta-
ging of pT3 (Figure 2).
After the surgery, one course of postoperative GC
treatment was administered. Evaluation with chest CT
according to RECIST guidelines (version 1.1) showed in-
creased size of the pulmonary metastatic tumors, judged
as progressive disease (PD). As a result, paclitaxel/
cisplatin/gemcitabine (PCG) combination therapy was
started. The PCG protocol consisted of GEM 1,000 mg/m2
and paclitaxel (PTX) 80 mg/m2 on non-dialysis days 1 and
8 plus CDDP 35 mg/m2 on dialysis day 2. This course was
repeated every three weeks.Figure 1 Abdominal computed tomography (CT) scan of the
patient. Abdominal CT scan prior to surgery showed a mass
measuring 6.4 × 3.7 cm in the transplanted kidney. A double-J
ureteral stent was placed.After two courses of PCG, pulmonary metastatic tu-
mors showed a 45% size reduction on chest CT, judged
as a partial response (PR). After seven courses of PCG
chemotherapy, CT demonstrated the disappearance of
all pulmonary metastatic tumors, judged as a complete
response (CR) (Figure 3). Toxicity was evaluated using
the Common Terminology Criteria for Adverse Events
(CTCAE) as a grade 2 neutropenia. There was no severe
toxicity. Currently, the patient has been tumor-free for
54 months following treatment.
Discussion
The overall incidence of de novo malignancies after renal
transplantation is much higher than that in the general
population because the former patients receive immuno-
suppressive therapy [6]. The risk of post-transplant UC is
higher among patients with aristolochic acid nephropathy
(AAN) (also called Chinese-herb nephropathy) [7] and
those among patients with analgesic nephropathy (AN)
because of prior analgesic abuse [8]. Several cases of UC
(bladder, ureter, and renal pelvis involvement) have been
reported in renal transplant patients without AAN or AN
[9,10]. Renal pelvis cancer following a kidney transplan-
tation almost occurs in the native kidney. The cause is un-
known, but post-transplant UC of a renal allograft rarely
occurs in the long-term postoperative period [11-13]. To
detect malignancies, an intensive follow-up regimen in-
cluding urine cytology should be adopted after renal
transplantation [14].
MVAC combination chemotherapy is the standard
regimen for locally advanced or metastatic UC [1]. A
combination of gemcitabine and cisplatin (GC) has
shown similar survival times compared with MVAC but
with better safety [2]. GC is now considered to be
another standard regimen for patients with locally ad-
vanced or metastatic UC.
However, an effective treatment strategy has not yet
been established for patients who show resistance to
initial treatment such as GC therapy. Some authors have
reported the efficacy of gemcitabine/paclitaxel (GEM/
PTX) combination therapy and the PCG combination
therapy that we evaluated in our study [15-17].
The overall response rate (complete or partial) with GEM/
PTX treatment following initial cisplatin or carboplatin-
based therapy ranges from 60 to 66.7% [15,16]. With PCG
therapy, an overall response rate of 77.6% and median sur-
vival time of 24 months have been reported, and 8.6% of
the patients in this study had received prior adjuvant
chemotherapy [17]. A randomized phase III study has
been performed looking at the use of GC and PCG for
locally advanced or metastatic UC; the PCG response rate
was 55.5%, significantly higher than the 43.6% response
rate with GC therapy [18]. In this study, the addition of
paclitaxel to the GC combination provided a 3.1-month
Figure 2 Hematoxylin & eosin (HE) staining. Microscopic appearance showed urothelial carcinoma, grade3. Some of the nuclei were very
large, irregular, and hyperchromatic.
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PCG versus 12.7 months for GC), but this did not reach
significance. Our case report shows that patients can sur-
vive for a long-period of time after PCG treatment. Thus,
PCG has potential as a novel first or second-line chemo-
therapy regimen for locally advanced or metastatic UC.Figure 3 Three phases of chest CT scans showing the metastatic tum
B, Reduction of the tumors after two courses of PCG. C, Disappearance of allIt is important to be able to predict which regimen is
effective in patients with UC before the initiation of
chemotherapy, and we should be able to avoid ineffec-
tive treatment. The survival rate of metastatic bladder
cancer patients treated with either GC or PCG is signifi-
cantly higher among patients with low ERCC1 levelsors. A, Before paclitaxel, cisplatin, and gemcitabine (PCG) chemotherapy.
metastatic tumors after seven courses of PCG.
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prognosis prediction factor connected with platinum-
based therapy for UC [19]. RRM1 has also been iden-
tified as a significant indicator of survival in patients
receiving GC, with low expression levels correlating with
greater survival benefit [20]. However, biomarkers indi-
cating which regimen, GC or PCG, was more effective
were not expressed.
In this way, personalized medicine based on biomarkers
has not been completely established yet, it would make a
remarkable contribution to cancer therapy in the near
future.
For dialysis patients, although it is possible to give
GEM and PTX on non-hemodialysis days at the same
dosage as in patients with normal renal function, it is
necessary to reduce the dose of cisplatin by 50% to avoid
nephrotoxicity; thus, hemodialysis initiation one hour
after injection is recommended [21,22]. With these mo-
difications, the plasma level of free cisplatin available for
anti-tumor activity is almost the same as in patients with
normal renal function [22]. There have been no reports
of PCG treatment for hemodialysis patients; however,
PCG was safely performed in our case.
Conclusions
The prognosis for metastatic UC is poor, with an average
survival of less than six months for untreated patients
[23]. Therefore, effective chemotherapy is needed for
advanced or metastatic UC. This is the first report de-
scribing PCG combination therapy for metastatic UC
arising in a transplanted renal allograft. PCG may have
shown successful outcomes in our reported case, but
further analyses on larger patient groups would be
required to provide stronger evidence to support this
therapeutic intervention.
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